Univest
Univest
  • Markets

AVIENCE BIOMEDICALS LTD Hits Upper Circuit on NSE, 28 September 2026

  • September 28, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
AVIENCE BIOMEDICALS LTD Hits Upper Circuit on NSE, 28 September 2026

On 28 September 2026, AVIENCE BIOMEDICALS LTD (AVIENCE) hit the upper circuit on NSE at Rs 376.25, a 10% positive move from the previous close of Rs 342.05. The company’s market cap stood at Rs 187.62 crore. The upper circuit price for the session was Rs 376.25.

The move was driven by buying interest against the exchange-defined price band. At the time of writing the stock was locked at its upper circuit level, which makes the session worth noting for short-term market participants.

Table of Contents

Toggle
  • Key Takeaways
  • Key Market Data
  • Price Action and Trading Activity
  • Why AVIENCE BIOMEDICALS LTD Hit Upper Circuit
  • What the Upper Circuit Means
  • AVIENCE BIOMEDICALS LTD Fundamentals and Valuation
  • Peer and Sector Context
  • Technical Snapshot
  • What Readers Should Know
  • Frequently Asked Questions
    • Why did AVIENCE BIOMEDICALS LTD hit upper circuit on 28 September 2026?
    • What was AVIENCE share price on 28 September 2026?
    • What was the upper circuit price for AVIENCE?
    • What is AVIENCE BIOMEDICALS LTD’s market cap and PE ratio?
    • Which exchange and data source were used?
    • Does hitting an upper circuit mean AVIENCE BIOMEDICALS LTD is a buy or a sell?
    • Can you buy or sell AVIENCE BIOMEDICALS LTD shares when the stock is at the upper circuit?
    • What happens the next trading session after an upper circuit?
    • What is the upper circuit limit set at for Indian stocks?
  • Footer Disclosure

Key Takeaways

  • AVIENCE BIOMEDICALS LTD (AVIENCE) hit the upper circuit on NSE at Rs 376.25 on 28 September 2026.
  • The session move was +10% against a previous close of Rs 342.05.
  • Market capitalisation stood at Rs 187.62 crore with a PE ratio of 21.43.
  • No official company announcement or verified catalyst was confirmed at the time of writing.
  • A price band is an exchange trading rule, not a view on the company or a recommendation.

Key Market Data

Metric Value
Stock AVIENCE BIOMEDICALS LTD
Current Price / LTP Rs 376.25
Day Move 10%
Previous Close Rs 342.05
Day Open Rs 346
Day High Rs 376.25
Day Low Rs 333
Upper Circuit Price Rs 376.25
Upper Circuit Limit Rs 376.25
Market Cap Rs 187.62 crore
Selected Exchange NSE
PE Ratio 21.43

All figures above are as of 28 September 2026, sourced from Univest market data for the NSE listing. Only fields present in the source for this session are shown.

Price Action and Trading Activity

AVIENCE BIOMEDICALS LTD opened at Rs 346 on NSE, compared with a previous close of Rs 342.05. During the session, the stock traded between Rs 333 and Rs 376.25 before touching the upper circuit price of Rs 376.25.

The absolute day change was Rs 34.2, while the percentage move was 10%. The event figures are kept to a single exchange so the numbers stay comparable.

The selected exchange matters because price bands, day range and previous-close values can differ across exchanges. This article uses NSE consistently for the event table and narrative. The stated upper circuit limit for the session was Rs 376.25, which is the level the price reached.

Why AVIENCE BIOMEDICALS LTD Hit Upper Circuit

AVIENCE BIOMEDICALS LTD hit the upper circuit after buying interest pushed the stock to its exchange-defined price band. No official company announcement or verified external catalyst was confirmed at the time of writing, so the move should be read primarily through price action and market sentiment.

Because no verified catalyst was available, this article does not attribute the move to earnings, corporate action, sector news, or market rumours. If a confirmed announcement becomes available later, it should be added as a separate update.

Within the session the stock reached the upper circuit level of Rs 376.25.

What the Upper Circuit Means

An upper circuit is the maximum price level a stock is allowed to reach during a trading session under the applicable exchange price band. For AVIENCE BIOMEDICALS LTD, the captured upper circuit price was Rs 376.25 on 28 September 2026.

The circuit mechanism is meant to slow extreme price movement and keep trading orderly. It is a market-structure fact, not a return forecast. In this article, the upper circuit explains what happened in the session and where the price band was reached.

AVIENCE BIOMEDICALS LTD Fundamentals and Valuation

Available market data gives a fuller picture than price action alone. For AVIENCE BIOMEDICALS LTD, PE ratio was 21.43, PB ratio was 3.54, book value was Rs 96.66, EPS was 15.96, ROE was 49.9%, ROCE was 34.16%, dividend yield was 0% and debt-to-assets ratio was 0.97, on a market cap of Rs 187.62 crore. These are available financial indicators and should not be read as a buy, sell, or hold view.

At the reported PB ratio of 3.54, the market valued AVIENCE BIOMEDICALS LTD above its reported book value per share. That premium can reflect growth expectations, asset quality, or simply thin trading in a smaller counter.

For investors tracking upper circuit moves, these metrics help separate the price event from the broader financial profile. A sharp one-day move can attract attention, but valuation and return ratios still need to be reviewed separately.

Peer and Sector Context

AVIENCE BIOMEDICALS LTD belongs to the Medical Equipment/Supplies/Accessories industry within the Healthcare sector. The peer table below uses available companies from the same sector or industry to give broader valuation context.

Peer Company Market Cap PE PB ROE
Q-LINE BIOTECH LIMITED Rs 1559.37 crore 27.99 3.19 25.55%
3B Blackbio Dx Ltd. Rs 1256.07 crore 22.62 4.49 19.41%
LAXMI DENTAL LIMITED Rs 1099.49 crore 35.6 4.48 11.95%
Hemant Surgical Industries Ltd. Rs 895.81 crore 49.24 6.23 12.73%
Osel Devices Ltd. Rs 686.69 crore 23.48 4.17 30.09%

Several of these peers are far larger by market capitalisation than AVIENCE BIOMEDICALS LTD. Size differences change liquidity and cost of capital, so the table is sector context rather than a like-for-like ranking.

AVIENCE BIOMEDICALS LTD’s PE ratio was 21.43, compared with an available peer PE average of 31.79, calculated from the 5 peer companies that had a PE on record. This comparison is a valuation reference point, not a recommendation.

Want to know more? Log in to Univest for more stock insights.

Technical Snapshot

Technical indicators were limited in the latest market dataset, so this article does not draw a technical conclusion beyond the confirmed upper circuit event.

What Readers Should Know

The main confirmed fact is that AVIENCE BIOMEDICALS LTD hit the upper circuit on NSE at Rs 376.25 on 28 September 2026, with a 10% day move.

The practical limitation after an upper-circuit session is execution. Buyers queue at the band and sellers step back, so the quoted price is not necessarily a price you can transact at. The other limitation is that no official catalyst was confirmed at the time of writing.

Readers should treat upper circuit events as market updates, not standalone investment conclusions. The price band shows strong near-term interest, but follow-up analysis should consider business fundamentals, valuation, liquidity, risk, and confirmed company disclosures.

Frequently Asked Questions

Why did AVIENCE BIOMEDICALS LTD hit upper circuit on 28 September 2026?

The stock reached its upper price band after buying interest during the session. No official company announcement or verified external catalyst was confirmed at the time of writing.

What was AVIENCE share price on 28 September 2026?

The last traded price used in this article was Rs 376.25 on NSE. That price matched the upper circuit price captured for the event.

What was the upper circuit price for AVIENCE?

The upper circuit price was Rs 376.25. The stated exchange upper circuit limit was Rs 376.25. The event numbers in this article are aligned to NSE.

What is AVIENCE BIOMEDICALS LTD’s market cap and PE ratio?

AVIENCE BIOMEDICALS LTD’s market cap was Rs 187.62 crore. PE ratio was 21.43.

Which exchange and data source were used?

The selected exchange was NSE. The article uses Univest market data available at the time of generation, captured on 28 September 2026.

Does hitting an upper circuit mean AVIENCE BIOMEDICALS LTD is a buy or a sell?

No. A circuit is an exchange price-band rule that caps how far a stock can move in a single session. It carries no view on valuation or business quality and is not a recommendation. Any decision should rest on fundamentals, valuation, liquidity and your own risk tolerance.

Can you buy or sell AVIENCE BIOMEDICALS LTD shares when the stock is at the upper circuit?

It is usually difficult. At the upper circuit, buy orders queue up while sellers step back, so there may be no counterparty at the quoted price. Orders can stay unfilled until the band opens up or sellers return.

What happens the next trading session after an upper circuit?

There is no fixed outcome. The band resets each session, so the stock can open freely, hit the same band again, or reverse. The exchange can also revise the applicable band width. The useful signals to watch are whether the company files any disclosure explaining the move.

What is the upper circuit limit set at for Indian stocks?

Exchange price bands are commonly set at 2%, 5%, 10% or 20% depending on the security, and the applicable band can be revised by the exchange. For AVIENCE BIOMEDICALS LTD the stated limit was Rs 376.25. For this session, AVIENCE BIOMEDICALS LTD moved 10%.

Footer Disclosure

Uniresearch Global Pvt. Ltd.
Research Analyst
SEBI Registration Number- INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply